Company intelligence / Profile preview
Raphael Pharmaceutical Inc.
- Ownership
- Private
- Development stage
- Phase 1
Overview
The company has successfully completed a proof-of-concept clinical trial demonstrating that its highly purified cannabinoid formula reduces key parameters of rheumatoid arthritis. The formulation shows anti-inflammatory potential and may slow RA progression. Additional preclinical work supports further development in inflammatory diseases and oncology supportive care.[1][2]
- Therapeutic areas
- OncologyPulmonologyRheumatologyInfectious Diseases
- Modalities
- Highly purified cannabinoids (including cannabidiol oil)
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Raphael Pharmaceutical Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Raphael Pharmaceutical Inc..